Basic Science of Inflammatory Bowel Disease- focus on T cell biology and regulatory T cells in animal models of colitis Clinical Research in IBD - Project Leader for CCFC sponsored Multi-Centered Canadian Prospective Cohort study of Individuals at risk for Crohn's disease to identify the Genetic, Environmental and Microbial Factors triggering or causing Crohn's disease (GEM Project).

She is site-principal investigator and similarly successful contributor of patients for the CCFA Pediatric Crohn’s Disease Risk Stratification study, an inception cohort study in new onset Crohn’s disease.

However, more than 50% of rare diseases only appear during adulthood, such as Huntington disease, Crohn's disease, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, Kaposi's sarcoma, or thyroid cancer.

He is the Director of the North American PRO-KIIDS Data Co-ordinating Centre (fully funded by the Crohn’s and Colitis Foundation of America), on the steering committee for the RISK study (a multi-centre North American Cohort Study of Paediatric Crohn’s Disease), a founding member of the Physician IT Advisory Group at The Hospital for Sick Children, consults to numerous investigative sites throughout North America regarding IBD research data management and organization, and is a lead investigator on an NIH funded planning grant to establish a clinically focused multi-centre cohort study in Paediatric Ulcerative Colitis.

For these reasons, the CH.I. L.D. Foundation and CIHR-INMD are partnering to support the creation of a Canadian Children Inflammatory Bowel Disease Network: a Joint Partnership of CIHR and the CH.I. L.D. Foundation to define clinically relevant parameters to better understand Crohn’s disease and ulcerative colitis in children and teenagers and to improve the quality of patient care for patients and their families who suffer from these debilitating diseases.

In the past decade, great advances have been made in understanding the genetic predisposition and biology of a number of polygenic disorders relevant to the mandate of INMD including, Crohn's disease, ulcerative colitis, diabetes, polycystic kidney diseases, and disorders of lipid metabolism.